Literature DB >> 1671050

Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state.

T Tada1, S Ohzeki, K Utsumi, H Takiuchi, M Muramatsu, X F Li, J Shimizu, H Fujiwara, T Hamaoka.   

Abstract

The present study investigates the nature of humoral component(s) generated in tumor-bearing hosts to induce immune dysfunction of T cells. Cell-free ascitic fluid and culture supernatant (SN) were obtained from the ascites and cultures allowing MH134 hepatoma cells to grow. These ascites and SN samples were tested for their abilities to influence the generation of CTL responses to TNP and alloantigens. The generation of the anti-TNP CTL responses that require self H-2-restricted CD4+ Th cells was markedly suppressed by addition of the ascites or SN under conditions in which these samples did not inhibit anti-allo CTL responses capable of using alternate pathways of allo-restricted CD4+ and CD8+ Th. The activation of CD8+ CTL precursors and CTL activity were also resistant to the ascites or SN. The ascites- or SN-induced suppressive effect to which CD4+ Th were most susceptible was found to be mediated by transforming growth factor-beta (TGF-beta) activity, because: 1) the TGF-beta activity was detected in the MH134 ascites and culture SN; 2) the suppression of CD4+ Th function required for anti-TNP CTL responses was almost completely prevented by addition of anti-TGF-beta antibody to cultures and; 3) rTGF-beta also induced similar patterns of immunosuppression to those observed by ascites or SN. These results indicate that TGF-beta produced by tumor cells induces deleterious effects on T cell, especially on the CD4+ Th subset, and provide an explanation for the molecular mechanism underlying the previously observed CD4+ Th-selective suppression in the tumor-bearing state.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671050

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  Circulating immunoglobulin-bound transforming growth factor beta at a late tumour-bearing stage impairs antigen-specific responses of CD4+ T cells.

Authors:  M Harada; K Tatsugami; M Nomoto; K Nomoto
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

2.  A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis.

Authors:  R Hernández-Pando; H Orozco-Esteves; H A Maldonado; D Aguilar-León; M M Vilchis-Landeros; D A Mata-Espinosa; V Mendoza; F López-Casillas
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

3.  Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta.

Authors:  M R Young; M A Wright; M Coogan; M E Young; J Bagash
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 4.  Immunotherapy for head and neck cancer: advances and deficiencies.

Authors:  Anna-Maria De Costa; M Rita I Young
Journal:  Anticancer Drugs       Date:  2011-08       Impact factor: 2.248

5.  Adiponectin receptors are downregulated in human gastric cancer.

Authors:  Kensuke Otani; Joji Kitayama; Takao Kamei; Daisuke Soma; Hideyo Miyato; Toshimasa Yamauchi; Takashi Kadowaki; Hirokazu Nagawa
Journal:  J Gastroenterol       Date:  2010-03-25       Impact factor: 7.527

6.  Tumor-immunotherapy with the use of tumor-antigen-pulsed antigen-presenting cells.

Authors:  J P Zou; J Shimizu; K Ikegame; H Takiuchi; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

7.  Inhibition of murine nephritogenic effector T cells by a clone-specific suppressor factor.

Authors:  C M Meyers; C J Kelly
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

8.  Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression.

Authors:  J A Reed; N S McNutt; V G Prieto; A P Albino
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

9.  Lymphocytes infiltrating colorectal cancer have low proliferative capacity but can secrete normal levels of interferon gamma.

Authors:  W J Bateman; I Donnellan; I A Fraser; L S Wong; A G Morris
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

10.  Interactions between interferon gamma and retinoic acid with transforming growth factor beta in the induction of immune recognition molecules.

Authors:  R Darley; A Morris; J Passas; W Bateman
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.